[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-1890":3,"doc-seo-1890":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":19,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"table_of_contents":24,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},1890,2336464648746,"Skyler","https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c",7,"Healthcare","Same-Day Post-Therapy Imaging With a New Generation Whole-Body Digital SPECT/CT for Assessing Treatment Response to [177Lu]Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer","Same-day quantitative whole-body digital SPECT/CT was evaluated for early treatment response assessment after [177Lu]Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer. In 68 retrospectively treated men, imaging performed 1–4.9 h post-infusion correlated lesion-based metrics (Lu-TTV) with overall survival and PSA progression-free survival, while SUVmax/SUVmean did not. The approach was feasible and well tolerated, but limited by small lesion detection and potential flare-up effects.","cbCainZ559ppJBly","https://ap.wps.com/l/cbCainZ559ppJBly","pdf",1715870,5,1,10,"English","en","",1776249683,25,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":23,"slug":31,"title":13,"keywords":24,"description":14,"schema_data":32,"social_meta":67,"head_meta":70,"extra_data":72,"updated_unix":25},105,"same-day-post-therapy-imaging-with-a-new-generation-whole-body-digital-spectct-for-assessing-treatment-response-to-177lulu-psma-617-in-metastatic-castration-resistant-prostate-cancer",{"@graph":33,"@context":66},[34,51],{"@type":35,"itemListElement":36},"BreadcrumbList",[37,41,45,48],{"item":38,"name":39,"@type":40,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":42,"name":43,"@type":40,"position":44},"https://docshare.wps.com/document/","Document",2,{"item":46,"name":12,"@type":40,"position":47},"https://docshare.wps.com/document/healthcare/",3,{"item":49,"name":13,"@type":40,"position":50},"https://docshare.wps.com/document/same-day-post-therapy-imaging-with-a-new-generation-whole-body-digital-spectct-for-assessing-treatment-response-to-177lulu-psma-617-in-metastatic-castration-resistant-prostate-cancer/1890/",4,{"url":49,"name":13,"@type":52,"author":53,"headline":13,"publisher":55,"fileFormat":58,"description":14,"dateModified":59,"datePublished":60,"encodingFormat":58,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":54},"Person",{"url":38,"name":56,"@type":57},"DocShare","Organization","application/pdf","2026-06-01","2026-04-15",true,{"@type":63,"interactionType":64,"userInteractionCount":19},"InteractionCounter",{"@type":65},"ViewAction","https://schema.org",{"og:url":68,"og:type":69,"og:title":13,"og:site_name":56,"og:description":14},"https://docshare.wps.com/document/same-day-post-therapy-imaging-with-a-new-generation-whole-body-digital-spectct-for-assessing-treatment-response-to-177lulu-psma-617-in-metastatic-castration-resistant-prostate-cancer/1890","article",{"robots":71,"canonical":68},"index,follow",{"doc_id":7,"site_id":30}]